In 476 virologically suppressed adolescents with HIV in sub-Saharan Africa, 8-weekly injectable cabotegravir-rilpivirine beat daily oral TLD: confirmed viral rebound by week 96 was 0.9% vs 6.4% (difference -5.5%), non-inferior and superior.
RCTn = 476
Bwakura-Dangarembizi et al. Switch to injectable cabotegravir-rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial